TEGRETOL CR CARBAMAZEPINE200MG TABS 50S

KSh1,254.00

This medication is known as an anticonvulsant or anti-epileptic drug. It is also used to relieve certain types of nerve pain (such as trigeminal neuralgia).Tegretal CR 200 Divitabs is an anti-epileptic medicine used to treat epilepsy. It helps prevent certain types of seizures (fits)

SKU: DP11309 Category:

INDICATIONS.

Epilepsy – generalised tonic-clonic and partial seizures. Tegretol Prolonged Release is indicated in newly diagnosed patients with epilepsy and in those patients who are uncontrolled or unable to tolerate their current anti-convulsant therapy.

Note: Carbamazepine is not usually effective in absences (petit mal) and myoclonic seizures. Moreover, anecdotal evidence suggests that seizure exacerbation may occur in patients with atypical absences.

The paroxysmal pain of trigeminal neuralgia.

For the prophylaxis of manic-depressive psychoses in patients unresponsive to lithium therapy.

DOSAGE.

Epilepsy

Indicated for the treatment of partial seizures with complex symptomatology (eg, psychomotor, temporal lobe), generalized tonic-clonic seizures (grand mal), and mixed seizure patterns, which include the seizure types listed here or other partial or generalized seizures

Maintenance dose range: 800-1200 mg/day PO in divided doses

Therapeutic range: 4-12 mg/L (16.9-50.8 micromoles/L)

Maximum dose of 1600 mg/day recommended (rarely, some patients have required 1.6-2.4 g/day)

Tablet (immediate-release)

Initial: 200 mg PO q12hr

Increase qWeek by 200 mg/day divided PO q6-8hr

Tablet/capsule (extended-release)

Initial: 200 mg PO q12hr

Increase qWeek by 200 mg/day PO divided q12hr

Oral suspension

Initial: 10 mL (200 mg) PO q6hr

Increase qWeek by up to 200 mg/day PO divided q6-8hr

IV solution

Indicated as replacement therapy in adults for PO carbamazepine formulations, when PO administration is temporarily not feasible

Approved as temporary use (ie, ≤7 days) for the following seizure types

Partial seizures with complex symptomatology

Generalized tonic-clonic seizures

Mixed seizure patterns which include the above, or other partial or generalized seizures

Dose

The total daily dose of carbamazepine IV is 70% of the total daily PO dose from which patients are being

Equally divide the total daily dose of the IV in four 30-minute infusions, separated by 6 hr

Patients should be switched back to oral carbamazepine administration at their previous total daily oral dose and frequency of administration as soon as clinically appropriate

IV administration has not been studies for >7 days

Limitations of use

Not indicated for absence seizures (including atypical absence); carbamazepine has been associated with increased frequency of generalized convulsions in these patients

Trigeminal Neuralgia

Indicated for pain associated with trigeminal neuralgia; beneficial results have also been reported in glossopharyngeal neuralgia; carbamazepine is not a simple analgesic and should not be used for the relief of trivial aches or pains

Maintenance dose range: 400-800 mg/day PO in divided doses; attempts to reduce or discontinue the drug should be made at least every 3 months throughout the treatment period

Maximum dose of 1200 mg/day recommended

Tablet (immediate-release)

Initial: 200 mg/day on day 1 divided q12hr

Increase by up to 200 mg/day in increments of 100 mg q12hr, to dose range of 400-800 mg/day divided twice daily; not to exceed 1200 mg/day

Tablet/capsule (extended-release)

Initial (XR tablet): 200 mg/day PO on day 1 divided q12hr

Initial (XR capsules): 200 mg PO once on the first day; may increase dose by up to 200 mg/day using increments of 100 mg q12hr to reach an effective/tolerated dose; not to exceed 1200 mg/day

Increase by up to 200 mg/day in increments of 100 mg q12hr, to dose range of 400-800 mg/day divided twice daily; not to exceed 1200 mg/day

Oral suspension

Initial: 200 mg PO on day 1 divided q6hr

Increase by up to 200 mg/day in increments of 50 mg q6hr, to dose range of 400-800 mg/day divided twice daily; not to exceed 1200 mg/day

Bipolar Mania

Equetro

Indicated for treatment of patients with acute manic or mixed episodes associated with bipolar I disorder

Initial: 200 mg PO q12hr

Increase by increments of 200 mg/day; not to exceed 1600 mg/day

Dosage Modifications

Renal impairment

Glomerular filtration rate <10 mL/min: Administer 75% of dose and monitor

Peritoneal dialysis and hemodialysis: Administer 75% of dose and monitor

Hepatic impairment

Use caution; drug is metabolized primarily in the liver

Restless Legs Syndrome (Off-label)

100-600 mg PO qHS for up to 5 weeks

Schizophrenia (Off-label)

200-1300 mg/day for 2.5-8 weeks

Postherpatic Neuralgia

100-200 mg PO qDay; may increase slowly to 1200 mg/day

ADVERSE EFFECTS.

Ataxia

Dizziness

Drowsiness

Nausea

Vomiting

Dry mouth

Stevens-Johnson syndrome

Hepatic failure

Punctate cortical lens opacities

Syndrome of inappropriate antidiuretic hormone secretion (SIADH).

0